| 今开：21.07 | 昨收：20.96 |
| 最高：21.54 | 最低：21.07 |
| 涨停价：0.0 | 跌停价：0.0 |
| 总市值：1.806243226E9 |
确定性required03-25 20:06
$Syndax制药(SNDX)$ 在2024年预计将取得以下主要成果：
Axatilimab的生物制品许可申请（BLA）获得FDA的优先审查：Axatilimab是一种针对慢性移植物抗宿主病（GVHD）的治疗药物，FDA已接受其BLA并授予优先审查地位，审批决定预计将在2024年8月28日前做出。
Revumenib的新药申请（NDA）提交给...查看全文
Syndax(SNDX)02-10 05:05
$Syndax制药(SNDX)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001562180-24-001218 Size: 7 KB 网页链接查看全文
Syndax(SNDX)02-28 06:25
$Syndax制药(SNDX)$ S-8 Securities to be offered to employees in employee benefit plans Accession Number: 0001193125-24-048118 Act: 33 Size: 86 KB 网页链接查看全文
Syndax(SNDX)02-28 05:05
$Syndax制药(SNDX)$ 8-K Current report, items 2.02 and 9.01 Accession Number: 0000950170-24-021086 Act: 34 Size: 359 KB 网页链接查看全文
Syndax(SNDX)02-08 23:25
$Syndax制药(SNDX)$ SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals Accession Number: 0000902219-24-000134 Act: 34 Size: 37 KB 网页链接查看全文
Syndax(SNDX)02-14 10:45
$Syndax制药(SNDX)$ SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals Accession Number: 0000919574-24-001234 Act: 34 Size: 167 KB 网页链接查看全文
Syndax(SNDX)02-10 05:05
$Syndax制药(SNDX)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001562180-24-001217 Size: 7 KB 网页链接查看全文
Syndax(SNDX)01-26 06:05
$Syndax制药(SNDX)$ SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals Accession Number: 0001086364-24-003711 Act: 34 Size: 13 KB 网页链接查看全文
Syndax(SNDX)03-18 19:15
$Syndax制药(SNDX)$ 8-K Current report, items 5.02, 7.01, and 9.01 Accession Number: 0000950170-24-032514 Act: 34 Size: 469 KB 网页链接查看全文
Syndax(SNDX)04-03 04:05
$Syndax(SNDX)$ DEF 14A Other definitive proxy statements Accession Number: 0000950170-24-040099 Act: 34 Size: 6 MB 网页链接查看全文
智通财经APP预告，2021年5月12日，港美股上市公司活动及香港重要财经会议信息情况如下： 00:00 AECOM(ACM.US) AECOM(ACM.US)2021年第一季度业绩电话会 网络转播 04:30 Syndax Pharmaceuticals Inc(SNDX.US) Syndax Pharmaceuticals Inc(... 网页链接
$Syndax(SNDX)$ ARS Annual Report to Security Holders Accession Number: 0000950170-24-040230 Act: 34 Size: 2 MB 网页链接
$Syndax(SNDX)$ DEF 14A Other definitive proxy statements Accession Number: 0000950170-24-040099 Act: 34 Size: 6 MB 网页链接
$Syndax(SNDX)$ DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material Accession Number: 0000950170-24-040128 Act: 34 Size: 2 MB 网页链接
$Syndax制药(SNDX)$ 8-K Current report, items 5.02, 7.01, and 9.01 Accession Number: 0000950170-24-032514 Act: 34 Size: 469 KB 网页链接
$Syndax制药(SNDX)$ S-3ASR Automatic shelf registration statement of securities of well-known seasoned issuers Accession Number: 0001193125-24-048135 Act: 33 Size: 2 MB 网页链接
$Syndax制药(SNDX)$ S-8 Securities to be offered to employees in employee benefit plans Accession Number: 0001193125-24-048118 Act: 33 Size: 86 KB 网页链接
$Syndax制药(SNDX)$ 10-K Annual report [Section 13 and 15(d), not S-K Item 405] Accession Number: 0000950170-24-021253 Act: 34 Size: 12 MB 网页链接
$Syndax制药(SNDX)$ 8-K Current report, items 2.02 and 9.01 Accession Number: 0000950170-24-021086 Act: 34 Size: 359 KB 网页链接
$Syndax制药(SNDX)$ SC 13G Statement of acquisition of beneficial ownership by individuals Accession Number: 0001085146-24-001353 Act: 34 Size: 44 KB 网页链接
$Syndax制药(SNDX)$ SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals Accession Number: 0000902664-24-001533 Act: 34 Size: 102 KB 网页链接